There appears to be widespread and ongoing confusion amongst industry as to which specific coded indications are considered by the Therapeutic Goods Administration (TGA) to be restricted representations requiring gazettal prior to being advertised to consumers.

The CHC was recently made aware of the TGA clarifying its position on the use of the term ‘arthritis’ in advertising. The CHC maintains that this issue be addressed as part of the permitted indications project and labelling reforms, however in the meantime advertising of these indications needs to be clarified.

Click here to read the Alert.